Retinoids in head and neck chemoprevention

Proceedings of the Society for Experimental Biology and Medicine

Volumn 216, Issue 2, 1997, Pages 283-290

  Papadimitrakopoulou, Vali A ^a   Hong, Waun K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ETRETINATE; FENRETINIDE; ISOTRETINOIN; N (4 CARBOXYPHENYL)RETINAMIDE; RETINOL;

ARTICLE; CANCER PREVENTION; CANCER RESEARCH; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HEAD AND NECK CANCER; HUMAN; PROGNOSIS; REGULATORY MECHANISM;

EID: 0030762253     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-216-44179     Document Type: Article

References (70)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 328:184-193, 1993.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. CA Cancer J Clin 46:8-9, 1996.
3. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41:184-197, 1988.
4. Farber E. The multistep nature of cancer development. Cancer Res 44:4217-4223, 1984.
5. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratifies squamous epithelium: Clinical implications of multicentric origin. Cancer 6:963-968, 1953.
6. Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, Laramore GE, Marcial VA, Davis LW, Cox JD. Second malignancies in patients who have head and neck cancers: Incidence, effect on survival and implications for chemoprevention based on the RTOG experience. Int J Radiat Oncol Biol Phys 17:449-456, 1989.
7. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK. Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst 82:555-560, 1990.
8. Hicks RM. The scientific basis for regarding vitamin A and its analogs as anticarcinogenic agents. Proc Nutr Soc 43:83-93, 1983.
9. Moon RC, Itri L. Retinoids and cancer. In: Sporn MB, Roberts AB, Goodman DS, Eds. The Retinoids. Orlando, FL: Academic Press, pp 327-371, 1984.
10. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 605:33-39, 1980.
11. Shklar G, Schwartz J, Grau D, Trickler DP, Wallace KD. Inhibition of hamster buccal pouch carcinogenesis by 13-cis-retinoic acid. Oral Surg 50:45-52, 1980.
12. Lotan R, Nicolson GL. Inhibitory effects of retinoic acid or retinyl acetate on the growth of untransformed, transformed and tumor cells in vitro. J Natl Cancer Inst 59:1717-1722, 1977.
13. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoid acid. Proc Natl Acad Sci U S A 77:2936-2940, 1980.
14. Jetten AM, Nervi C, Vollberg TM. Control of squamous differentiation in tracheobronchial and epidermal epithelial cells: Role of retinoids. J Natl Cancer Inst Monograph 13:93-100, 1992.
15. Reiss M, Pitman SW, Sartorelli AC. Modulation of the terminal differentiation of human squamous carcinoma cells in vitro by all-trans-retinoic acid. J Natl Cancer Inst 74:1015-1023, 1985.
16. Fuchs E, Green H. Regulation of terminal differentiation of cultured human keratinocytes by vitamin A. Cell 25:617-625, 1981.
17. Thiele C, Deutsch LA, Israel MA. The expression of multiple protooncogenes is differentially regulated during retinoic acid induced maturation of human neuroblastoma cell line. Oncogene 3:281-288, 1988.
18. Gudas LJ, Sporn MB, Roberts AB. Cellular biology and biochemistry of the retinoids. In: Sporn MB, Roberts AB, Goodman DS, Eds. The Retinoids: Biology, Chemistry, and Medicine. New York: Raven Press, pp 443-520, 1994.
19. Lotan R. Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic-acid-induced growth inhibition. Cancer Res 39:1014-1019, 1979.
20. Mangelsdorf D, Umesono K, Evans RM. The retinoid receptors. In: Sporn MB, Roberts AB, Goodman DS, Eds. The Retinoids: Biology, Chemistry, and Medicine (2nd ed). New York: Raven Press, pp 319-349, 1994.
21. Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330:444-459, 1987.
22. Leid M, Kastner P, Chambon P. Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem Sci 17;427-433, 1992.
23. Nagy L, Thomazy VA, Shipley GL, Fesus L, Lamph W, Heyman RA, Chandraratna RAS, Davies PJA. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 15:3540-3551, 1995.
24. Shule R, Rangarajan P, Yang N, Kleiwer S, Ransone LJ, Bolado J, Verma IM, Evans RM. Retinoic acid is a negative regulator of AP-1 responsive genes. Proc Natl Acad Sci U S A 88:6092-6096, 1991.
25. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harley E, Graupner G, Lu X-P, Pfahl M. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature (Lond) 372:107-110, 1994.
26. Xu XC, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R. Differential expression of nuclear retinoid receptors in normal, premalignant and malignant head and neck tissues. Cancer Res 54:3580-3587, 1994.
27. Hu L, Crowe DL, Rheiwald JG, Chambon P, Gudas LJ. Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Cancer Res 51:3972-3981, 1991.
28. Houle B, Egly-Rochette C, Bradley WE. Tumor-suppressive effect of retinoid acid receptor β in human epidermoid lung cancer cells. Proc Natl Acad Sci U S A 90:985-989, 1993.
29. Lotan R, Xu X-C, Lippman SM, Roy JY, Lee JS, Lee JJ, Hong WK. Suppression of retinoic acid receptor β in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 332:1405-1410, 1995.
30. Lippman SM, Shin DM, Lee JJ, Batsakis JG, Lotan R, Tainsky MA, Hittelman WN, Hong WK. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 55:16-19, 1995.
31. Lee JS, Kim SY, Hong WK, Lippman SM, Ro JY, Gay ML, Hittelman WN. Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion. J Natl Cancer Inst 85:1951-1954, 1993.
32. Voravud N, Shin DM, Ro JY, Lee JS, Hong WK, Hittelman WN. Increased polysomies of chromosomes 7 and 17 during head and neck multistage tumorigenesis. Cancer Res 53:2784-2883, 1993.
33. Boyle JO, Koch W, Hruban RH, van der Riet P, Sidransky D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53:4477-4480, 1993.
34. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, Hittelman WN. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54:321-326, 1994.
35. Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, Heyne K, Shin HJC, Ro JY, Goepfert H, Hong WK, Hittelman WN. p53 expression: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 88:519-529, 1996.
36. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman SM, Hittelman WN, Hong WK. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Med 2:682-685, 1996.
37. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 56:2488-2492, 1996.
38. Serrano M, Hannon G, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond) 366:704-707, 1993.
39. INK4a in oral premalignant lesions. Oncogene 14:1799-1803, 1997.
40. Williams ME, Gaffey MJ, Weiss LM, Wilczynski SP, Schuuring E, Levine PA. Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 119:1238-1243, 1993.
41. Izzo J, Papadimitrakopoulou V, Lee JS, Ro JY, Li XQ, Hong WK, Hittelman WN. Role of Cyclin D1 in the multistep tumorigenesis process of head and neck squamous cell carcinomas (HNSCC). (abstract) Proc Am Assoc Cancer Res 37:3687, 1996.
42. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54:3153-3159, 1994.
43. Shin DM, Voravud N, Ro JY, Lee JS, Hong WK, Hittelman WN. Sequential upregulation of proliferating cell nuclear antigen in head and neck tumorigenesis: A potential biomarker. J Natl Cancer Inst 85:971-978, 1993.
44. Mao L, El-Naggar AK, Fan YH, Hong WK. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res 56:5600-5604, 1996.
45. Silverman S Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: A follow-up study of 257 patients. Cancer 53:563-568, 1984.
46. Hong WK, Endicott J, Itri L, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C, Toth BB, Kramer A, Dimery IW, Skipper P, Strong S. 13-cis retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986.
47. Lippman SM, Barsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, Hays GL, Goepfert H, Hong WK. Comparison of low-dose isotretinoin with β-carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20, 1993.
48. Papadimitrakopoulou VA, Hong WK, Lee JS, Martin JW, Lee JJ, Batsakis JG, Lippman SM. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: Long-term follow-up. J Natl Cancer Inst 89:257-258, 1997.
49. Costa A, Formelli F, Chiesa F, Decensi A, De Palo G, Veronesi U. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 54:20325-20375, 1994.
50. Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, Mariani L, Clerici M, Formelli F, Barzan A, Carrassi A, Pastorini A, Camerini T, Giardini R, Zurrida S, Minn FL, Costa A, De Palo G, Veronesi U. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide(4-HPR): Preliminary results. Oral Oncol Eur J Cancer 28:97-102, 1992.
51. Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Krishnan Nair M. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 40:93-101, 1988.
52. Han J, Jiao L, Lu Y, Sun Z, Gu QM, Scanlon KJ. Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo 4:153-160, 1990.
53. Bollag W, Peck R. Modulation of cell proliferation and differentiation by retinoids, cytokines, and their combination: Experimental and clinical aspects. In: Livera MA, Packer L, Eds. Retinoids: Progress in Research and Clinical Applications. New York: Dekker, pp 311-328, 1993.
54. Kolla V, Lindner DJ, Weihua X, Borden EC, Kalvakolanu DV. Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem 271:10508-10514, 1996.
55. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, Holdener E, Krakoff IH. 13-cRA plus interferon α-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241-246, 1992.
56. Healy GB, Gelber RD, Trowbridge AL, Grundfast KM, Ruben RJ, Price KN. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon: Results of a multicenter randomized clinical trial. N Engl J Med 319:401-407, 1988.
57. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: The overshadowing threat for patients with early stage disease. (editorial) Int J Radiat Oncol Biol Phys 17:691-694, 1989.
58. McDonald S, Haie C, Rubin P, Nelson D, Divers LD. Second malignant tumors in patients with laryngeal carcinoma: Diagnosis, treatment and prevention. Int J Radiat Oncol Biol Phys 17:457-465, 1989.
59. Licciardello JT, Spitz MR, Hong WK. Multiple primary cancer in patients with cancer of the head and neck: Second cancer of the head and neck, esophagus and lung. Int J Radiat Oncol Biol Phys 17:467-476, 1989.
60. Hong WK, Lippman SM, Itri LM, Karp D, Lee JS, Byers R, Schantz SP, Kramer AM, Lotan R, Peters LJ, Dimery IW, Brown WB, Goepfert H. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990.
61. Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: Long-term follow-up. J Natl Cancer Inst 84:140-141, 1994.
62. Bolla M, Lefur R, Ton Van J, Domenge C, Badet JM, Koskas Y, Laplanche A. Prevention of second primary tumors with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer 30A:767-772, 1994.
63. De Vries N, Van Zandwijk N, Pastorino U. The EUROSCAN study. Br J Cancer 64:985-989, 1991.
64. Pastorino U, Ifante M, Maioli M, Chiesa G, Buyse P, Rasmentz N, Clerici M, Soresi E, Valente M, Belloni PA, Ravasi G. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11:1216-1222, 1993.
65. Pastorino U, Van Zandwijk N, De Vries N, Dalesio O, Van Tinteren H. Results of the Euroscan trial. Proc Seventh World Conference on Lung Cancer. Lung Cancer 11:94-95, 1994.
66. Heyman RA, Mangelsdorf DF, Dyck JA, Stein RB, Eichele G, Evans RM, Thaller C. 9-cis-retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68:397-406, 1992.
67. Kurie JM, Lee JS, Griffin T, Lippman SM, Drum P, Thomas MP, Weber C, Bader M, Massimini G, Hong WK. Phase I trial of 9-cis retinoic acid in adults with solid tumors. Clin Cancer Res 2:287-293, 1996.
68. Miller VA, Rigas JR, Benedetti FM, Verret AL, Tong WP, Kris MG, Gill GM, Loewen GR, Truglia JA, Ulm EH, Warrell RP Jr. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin Cancer Res 2:471-475, 1996.
69. Shalinsky DR, Bishoff ED, Gregory ML, Lamph WW, Hayes JS, Heyman RA, Thomazy V, Davies PJA. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin Cancer Res 2:511-520, 1996.
70. Shalinsky DR, Bishoff ED, Lamph WW, Zhang L, Boehm MF, Davies PJA, Nazdan AM, Heyman RA. A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res 57:162-168, 1997.